Natixis Advisors
XENE icon

Natixis Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Natixis Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,564
Closed -$705K – 1747
2025
Q3 		$705K Buy
17,564
+140
+0.8% +$4.93K ﹤0.01% 1416
2025
Q2 		$545K Sell
17,424
-6,586
-27% -$215K ﹤0.01% 1452
2025
Q1 		$806K Buy
24,010
+456
+2% +$17.3K ﹤0.01% 1336
2024
Q4 		$923K Sell
23,554
-3,604
-13% -$149K ﹤0.01% 1322
2024
Q3 		$1.07M Buy
27,158
+7,564
+39% +$305K ﹤0.01% 1278
2024
Q2 		$764K Sell
19,594
-82
-0.4% -$3.28K ﹤0.01% 1329
2024
Q1 		$847K Sell
19,676
-1,617
-8% -$74.4K ﹤0.01% 1267
2023
Q4 		$980K Sell
21,293
-731
-3% -$25.8K ﹤0.01% 1212
2023
Q3 		$752K Buy
22,024
+4
+0% +$150 ﹤0.01% 1246
2023
Q2 		$848K Buy
22,020
+279
+1% +$11.1K ﹤0.01% 1203
2023
Q1 		$778K Buy
21,741
+249
+1% +$9.2K ﹤0.01% 1199
2022
Q4 		$847K Sell
21,492
-111
-0.5% -$4.04K ﹤0.01% 1186
2022
Q3 		$780K Buy
21,603
+2,224
+11% +$80K ﹤0.01% 1168
2022
Q2 		$590K Buy
+19,379
New +$586K ﹤0.01% 1243

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Natixis Advisors's XENE Position: Q4 2025 in Review

Natixis Advisors sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 17,564 shares — an estimated $705K sold.

Natixis Advisors first reported a position in XENE in Q2 2022 and held it in 14 quarters. The position peaked at $1.07M in Q3 2024. 245 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Natixis Advisors reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Natixis Advisors sold 17,564 Xenon Pharmaceuticals shares in Q4 2025, an estimated $705K.
  • Natixis Advisors first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Natixis Advisors's Xenon Pharmaceuticals position peaked at $1.07M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Natixis Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.